Table 2 Rhesus monkey anti-hypnozoite experiments
Drug Group | Mirincamycin dose (mg/kg/day)** | # cured monkeys/# treated monkeys | Day of parasitemic relapse | Days relapsed delayed beyond CQ group | AUC (ng*h/ml) on day 7 [mean] |
|---|---|---|---|---|---|
Treatment of initial parasitaemia | |||||
Chloroquine* | 0 | 0//2 | 11, 14 | na | na |
cis-mirincamycin (PO) + CQ* | 20 | 0//2 | 21, 21 | 8, 8 | 1681 |
cis-mirincamycin (PO) + CQ* | 40 | 0//2 | 34, 75 | 21, 62 | 7125 |
cis-mirincamycin (PO) + CQ* | 80 | 0//2 | 27, 33 | 14, 20 | 8878 |
trans-mirincamycin (PO) + CQ* | 20 | 0//2 | 18, 18 | 5, 5 | 1343 |
trans-mirincamycin (PO) + CQ* | 40 | 0//2 | 18, 21 | 5, 8 | 4056 |
trans-mirincamycin (PO) + CQ* | 80 | 0//2 | 29, 44 | 16, 31 | 9080 |
cis-mirincamycin (IV) + CQ* | 20 then 5 | 0//2 | 18, 18 | 5, 5 | 1922 |
trans-mirincamycin (IV) + CQ* | 20 then 5 | 0//2 | 18, 21 | 5, 8 | 1789 |